Still More Data on All-Oral Regimens for Rifampin-Resistant Tuberculosis

A multinational trial found a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin to be noninferior to standard treatment for rifampin-resistant tuberculosis.

Several trials have demonstrated the efficacy of bedaquiline-based regimens for drug-resistant tuberculosis (TB), although the utility of all-oral regimens has only been assessed in one country (NEJM JW Infect Dis May 2020 and N Engl J Med 2020 382:893; NEJM JW Infect Dis Mar 2022 and Am J Respir Crit Care Med 2022; 205:1214; NEJM JW Infect Dis Oct 2022 and N Engl J Med 2022; 387:810; and NEJM JW Infect Dis Nov 21 2022; [e-pub] and Lancet 2022 Nov 8; [e-pub]). In a two-stage, phase 2–3 trial involving 552 patients, investigators assessed the efficacy of three all-oral regimens for rifampin-resistant pulmonary TB. In stage 1, patients were assigned to standard care; oral therapy for 24 weeks with bedaquiline, pretomanid, and linezolid (BPaL)…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Still More Data on All-Oral Regimens for Rifampin-Resistant Tuberculosis

Topics

Reviewing Author